
Reverse Aging by 20 Years? The $101M XPRIZE Finalists Revealed
The $101 million XPRIZE Healthspan competition has revealed 10 finalists aiming to reverse aging by 20 years. Teams must restore muscle, cognition, and immune function by 10-20 years within 12 months. Here's a detailed analysis of all finalists and their clinical approaches.
Background of the Competition- Prize Money: Tiered from $61M (10-year improvement) to $81M (20-year improvement)
- Evaluation Criteria: Simultaneous improvement in the triad of aging (muscle, brain, immune system) with at least 20% responder rate
- Muscle Tests: 6-minute walk test and lower body power
- Cognition: Standardized computerized test battery
- Immune System: Blood tests for immune cell composition and inflammatory age
- Important Note: Epigenetic clocks are not winning criteria
1. Repurposed Drug Stacks
- Ageless RX (Ann Arbor, Michigan): Home protocol with naltrexone, metformin, NAD precursors, vitamin B12, rapamycin + GLP-1 agonist + somatrelin. 90-day pilot study showed improved biological age, but one heart attack case.
- NYC Vita Protocol (Mount Sinai): Low-dose rapamycin + spermidine + high-intensity training. Goal: Reduce inflammation and rejuvenate immune cells.
2. Regenerative Biologics
- Longevon (University of Miami): Lomecel-B (stem cell infusion). Phase 2b trial: 63-meter improvement in walk test after 9 months, but not significant at 180 days.
- God Lab (University of Tokyo): Developing extracellular vesicles (EVs) to clear senescent cells. 15-year reversal based on mouse models.
- Time Traveler (Japan): Supplement Exfall Fuji from parsley EVs. No peer-reviewed studies.
3. Precision Molecular & Gene Therapies
- Mitochondrial Allstars (University of Washington): Elamipretide (mitochondrial stabilizer). Single infusion improved energy production but no lasting effect.
- Minicircle (non-viral gene therapy): Circular DNA for follistatin (muscle growth) and klotho (brain health). Unblinded observational data from Honduras.
- Johns Hopkins / Suninflamm: CIO1 antibody targeting galectin-3 (inflammatory protein). Still in Phase 1 trial.
- PRG Essent (South Korea): Oral progerin inhibitor for premature aging. Unproven in normal aging.
- Retroepigen (Macau): Herbal + probiotic formula for tRNA modifications. Only cell studies, no human data.
- Timeline: 2026-2029: 12-month clinical trials overseen by University of Utah and UC San Diego
- Challenge: Can a single molecule rejuvenate three organ systems, or are combination therapies needed?
- Reality Check: Many finalists have limited human data. Expected interventions (e.g., thymus rejuvenation) are missing.
- New Standard: Not marketing, but clinical function â walking, thinking, immune protection
Which philosophy will win? Share your thoughts in the comments!






